



ROBERT R. MYERS, Ph.D.
PROFESSOR OF ANESTHESIOLOGY
PROFESSOR OF PATHOLOGY (NEUROPATHOLOGY)

ANESTHESIOLOGY RESEARCH, 0629
9500 GILMAN DRIVE
LA JOLLA, CALIFORNIA 92093-0629
(858) 534-6608 DIRECT
(858) 534-3865 OFFICE
(858) 534-1445 FAX
rmyers@ucsd.edu

August 3, 2009

BY ELECTRONIC FILING

Marlene H. Dortch
Secretary
Federal Communications Commission
445 12th Street, SW
Washington, D.C. 20554

Re: Amendment of Parts 2 and 95 of the Commission's Rules to Provide Additional Spectrum for the Medical Device Radiocommunication Service in the 413-457 MHz Band (ET Dkt. No. 09-36; RM-11404)

Dear Ms. Dortch:

I support expeditious Commission action to encourage deployment of medical micro-power network ("MMN") devices in the 413-457 MHz band.

I am Professor Emeritus in the Departments of Anesthesiology and Pathology at the University of California, San Diego, and former Senior Research Career Scientist in the Department of Veterans Affairs. My research work has focused on basic mechanisms of peripheral nerve degeneration and regeneration, and in this context the VA funded a major study using the Bion micro-power network devices to explore their safety and utility in managing nerve regeneration and pain. This is, of course, a major problem within the VA Healthcare System because of the tremendous physical, psychological, and financial burdens imposed by battlefield injuries. Currently, the available medical treatment options are limited, and the demand for better, more effective options continues to grow as these injuries and conditions take their toll on an increasing number of people and their families and friends.

I believe that the MMN technology developed by the Alfred Mann Foundation (AMF) provides a unique wireless approach that is unlike any commercially available medical treatment option. This technology, if successfully implemented, will revolutionize the medical treatment and therapy for millions of people suffering from debilitating neuromuscular injuries and conditions.

I believe that this groundbreaking technology is safe and will be proven to be effective in helping patients regain spinal cord and peripheral nerve function that will help them return to productive and rewarding lives. We urge the Commission to allocate the full amount of spectrum requested by AMF for MMN use and to adopt service and technical rules permitting MMN operation.

Sincerely,

Robert R. Myers
Robert R. Myers